ImmunoGen v. Vidal: Federal Circuit Affirms Anti-FOLR1 Immunoconjugate Patent Ruling
ImmunoGen, Inc. challenged a USPTO patentability determination on its anti-FOLR1 immunoconjugate dosing regimen application (US 14/509809) before the Federal Circuit. After 688 days, the court affirmed the ruling below, leaving the patent application’s validity status unchanged and closing a significant appellate chapter for antibody-drug conjugate IP.
Federal Circuit closes ImmunoGen’s ADC dosing-regimen patent appeal
ImmunoGen, Inc., a biopharmaceutical company specialising in antibody-drug conjugate (ADC) therapeutics, filed this appeal at the Court of Appeals for the Federal Circuit on 18 April 2023. The case concerned the patentability of US Application No. 14/509809, directed to anti-FOLR1 immunoconjugate dosing regimens — a technology underpinning ImmunoGen’s folate receptor-targeting oncology pipeline. The named defendant, Katherine K. Vidal, was sued in her capacity as Under Secretary of Commerce for Intellectual Property and Director of the USPTO.
The Federal Circuit issued its disposition on 6 March 2025, ordering the lower patentability determination affirmed. An affirmance at this level means the appellate panel found no reversible error in the USPTO’s or lower tribunal’s reasoning — the legal and factual conclusions reached below were upheld in full. For ImmunoGen, the affirmance forecloses further challenge on the same grounds at this court level, and the patent application remains subject to the adverse patentability finding that prompted the appeal.
At 688 days, the proceeding exceeded the typical Federal Circuit patent appeal timeline, suggesting the underlying patentability questions — likely centred on obviousness or written description for the dosing regimen claims — required careful appellate scrutiny. The basis of termination is recorded as ‘Appeal Dismissed,’ yet the verdict expressly states ‘AFFIRMED,’ which is consistent with a dismissal on the merits or a consolidated disposition; the public record does not clarify whether any procedural sub-issues were separately dismissed. ImmunoGen’s broader therapeutic strategy around mirvetuximab soravtansine (its lead FOLR1-targeting ADC) may be affected depending on which specific claims were at issue.
Filing to Appeal Dismissed in 688 days
688 days — longer than the median Federal Circuit patent appeal (~500 days)
Federal Circuit affirms: what the ruling means for both parties
Affirmance means the lower decision stands — no reversible error found
When the Federal Circuit affirms, it concludes that the tribunal below — here, likely the Patent Trial and Appeal Board or an examiner-level determination — committed no reversible legal or factual error. The appellate panel reviewed the patentability analysis under the applicable standard (typically de novo for legal questions, substantial evidence for factual ones) and found the outcome correct. No remand was ordered; the challenged determination is now final at this court level.
Appellate affirmance — merits upheldImmunoGen’s dosing-regimen claims remain subject to adverse patentability finding
The affirmance confirms that ImmunoGen’s anti-FOLR1 immunoconjugate dosing regimen application (US 14/509809) did not overcome the patentability hurdle identified below. The patent application’s enforceability and grant prospects are materially weakened. ImmunoGen’s remaining options are narrow: a petition for en banc rehearing or a certiorari petition to the Supreme Court, both of which face high rejection rates. The underlying FOLR1-targeting ADC commercial position may depend on separately granted patents.
Claims remain unpatented at this stageUSPTO’s patentability position validated by Federal Circuit
The USPTO, represented by Director Vidal, successfully defended its patentability determination on appeal. The affirmance validates the agency’s legal reasoning — whether based on obviousness, written description, or another ground — and reinforces institutional authority over ADC dosing regimen claim examination. Competitors and third parties who may have tracked this proceeding can now treat the adverse patentability finding as settled Federal Circuit precedent for similar claim structures.
USPTO position upheld on appealAffirmed rejection raises the bar for ADC dosing-regimen patent claims
For the broader ADC and oncology IP landscape, a Federal Circuit affirmance of a patentability rejection on dosing-regimen claims signals that such claims face rigorous scrutiny. Companies drafting or prosecuting similar immunoconjugate dosing claims — particularly those targeting folate receptors or analogous tumour-associated antigens — should treat this outcome as a prosecution risk signal. Freedom-to-operate analyses for competing FOLR1-directed therapeutics may be affected if the unpatented claims leave gaps in ImmunoGen’s exclusivity wall.
Higher bar for ADC dosing-regimen claimsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ImmunoGen, Inc. | Company | Biopharmaceutical ADC innovator — holder of US Application 14/509809Search in Eureka ↗ |
| Defendant | Katherine K. Vidal | Individual | Katherine K. Vidal, sued as USPTO Director in her official capacitySearch in Eureka ↗ |
| Plaintiff counsel | David Frazier | Attorney | Counsel for ImmunoGen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gabriel K. Bell | Attorney | Counsel for ImmunoGen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael A. Morin | Attorney | Counsel for ImmunoGen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Yi Sun | Attorney | Counsel for ImmunoGen, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins, LLP | Law Firm | Representing ImmunoGen, Inc.Search in Eureka ↗ |
| Defendant counsel | Thomas W. Krause | Attorney | Counsel for Katherine K. VidalSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED’ — is a merits disposition confirming the patentability determination below survived appellate review. The terse formulation is standard for Federal Circuit Rule 36 judgments or short-form orders, which affirm without extended written opinion when the panel finds no legal error warranting elaboration. The basis of termination field notes ‘Appeal Dismissed,’ which may reflect a consolidated procedural record, but the operative legal effect is an affirmance on the merits. ImmunoGen is bound by the outcome; the USPTO’s rejection reasoning now carries Federal Circuit imprimatur.
US14/509809 — Anti-FOLR1 Immunoconjugate Dosing Regimens
US Application No. 14/509809 (published as US20150132323A1) relates to dosing regimen methods for anti-FOLR1 immunoconjugates — engineered antibodies linked to cytotoxic payloads that selectively target folate receptor alpha (FOLR1), a protein overexpressed in ovarian, endometrial, and lung cancers. The application claims specific dose schedules and administration protocols designed to optimise therapeutic index for this class of ADC. Filed in the context of ImmunoGen’s established ADC platform, it represents the clinical translation layer of the company’s FOLR1-targeting research.
FOLR1-targeting ADCs occupy a commercially significant niche: ImmunoGen’s mirvetuximab soravtansine received FDA approval in 2022 for platinum-resistant ovarian cancer, making the surrounding patent estate strategically critical. Dosing-regimen patents serve as a secondary exclusivity layer beyond composition-of-matter claims, extending commercial protection into clinical practice. The failure of this application to achieve patentability — affirmed by the Federal Circuit — potentially shortens the effective exclusivity runway for FOLR1-directed ADC dosing and opens tactical space for biosimilar or competing therapeutic developers.
Should you run an FTO against US14/509809?
Any R&D team developing anti-FOLR1 antibody-drug conjugates, FOLR1-targeting bispecifics, or competing immunoconjugate dosing protocols should assess this application. Although the Federal Circuit has affirmed an adverse patentability finding — reducing the likelihood that US 14/509809 issues as granted — prosecution history and related continuations in ImmunoGen’s portfolio may still present claim-overlap risks. FTO clearance should map the full family, not this application alone.
PatSnap Eureka’s FTO Search Agent can rapidly identify all related ImmunoGen patent families claiming FOLR1-directed dosing regimens, surface prosecution history for US 14/509809 and its continuations, and flag active granted claims that could still constrain competing products. For oncology teams moving ADC candidates toward IND or clinical-stage development, an automated FTO sweep against this patent family is a low-cost, high-value step before committing significant R&D resources.
Run a freedom-to-operate analysis on US20150132323A1 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ADC & biopharma patentability appeals
Explore Federal Circuit cases involving antibody-drug conjugate patentability disputes, immunoconjugate dosing-regimen claims, and USPTO Director appeals in the oncology space.
What this case signals for the antibody-drug conjugate IP landscape
Federal Circuit affirmance of an ADC dosing-regimen rejection has direct implications for oncology IP strategy and prosecution planning.
Dosing-regimen claims for ADCs face heightened Federal Circuit scrutiny
This affirmance suggests that method-of-treatment or dosing-regimen claims for immunoconjugates must be drafted with considerable specificity and supported by robust clinical data. Prosecution teams working on FOLR1-directed or comparable ADC assets should audit pending claims against the USPTO positions upheld in this proceeding to pre-empt similar rejections.
Competitors gain freedom-to-operate confidence in the FOLR1 dosing space
With US 14/509809 claims unpatented following affirmance, companies developing competing anti-FOLR1 therapies or overlapping ADC dosing regimens have stronger grounds for FTO clearance in this specific claim space. Independent patent counsel should still confirm scope, but the appellate record now supports a narrower exclusivity perimeter for ImmunoGen in this domain.
ImmunoGen v Katherine — key questions answered
The Federal Circuit affirmed the lower patentability determination against ImmunoGen’s anti-FOLR1 immunoconjugate dosing regimen application (US 14/509809). The court found no reversible error in the USPTO’s position, closing the appeal on 6 March 2025 after 688 days of proceedings.
US Application No. 14/509809, published as US20150132323A1, is an ImmunoGen patent application directed to dosing regimen methods for anti-FOLR1 immunoconjugates — antibody-drug conjugates targeting folate receptor alpha. It claims specific dose schedules for administering FOLR1-directed ADCs in oncology settings, representing a clinical-use layer of patent protection for ImmunoGen’s ADC platform.
Katherine K. Vidal was named as the defendant in her official capacity as Under Secretary of Commerce for Intellectual Property and Director of the USPTO. In appeals challenging USPTO patentability determinations under 35 U.S.C. § 145 or related provisions, the agency director is the named opposing party, not the USPTO as an institution.
An affirmance confirms that the adverse patentability finding below was legally correct — ImmunoGen cannot use this application to obtain granted patent claims on these dosing regimens through the challenged grounds. ImmunoGen’s options are limited to en banc rehearing or Supreme Court certiorari, both statistically unlikely. The company’s FOLR1 exclusivity must rely on other granted patents in its portfolio.
The affirmance strengthens FTO arguments for competitors in the anti-FOLR1 ADC dosing space, since US 14/509809 has not achieved patentability on the challenged claims. However, FTO clearance should still encompass ImmunoGen’s broader patent family — including any continuations or divisionals that may carry overlapping claims — before drawing firm conclusions about the competitive landscape.
PatSnap Eureka searches patents and litigation data to answer instantly.